Japan Earthquake Disrupts Auto and Chip Supply Chains 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
CHARLESTON, S.C., May 01, 2018 -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) will announce its first quarter 2018 financial and operating results after market close on Monday, May 7, 2018. The Company will host a conference call to discuss these results on Tuesday, May 8, 2018 at 8:30 a.m. Eastern Time.
Participants may access the conference call by telephone using the following numbers:
- Toll-Free: 877-407-8029, Confirmation #13679691
- Toll: 201-689-8029, Confirmation #13679691
A replay will also be available on the Company’s website for a period of 30 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an orally available ghrelin agonist, to be used in the diagnosis of patients with adult growth hormone deficiency. Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit www.aezsinc.com.
Contact:
Aeterna Zentaris Inc.
James Clavijo
Chief Financial Officer
[email protected]
843-900-3201
